Citations (27)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (7)
Antonios Zikos, Marvin Balaan, Emily Hobart, Sandeep Bansal, Rihab Saeed, Tariq Cheema & Deborah Gentile. (2024) Efficacy of bronchial thermoplasty in a patient panel with uncontrolled severe persistent asthma. Journal of Asthma 0:0, pages 1-9.
Read now
Read now
Michael Bogart, Guillaume Germain, François Laliberté, Malena Mahendran, Mei Sheng Duh, Kristi DiRocco, Stephen G Noorduyn, Rosirene Paczkowski & Ronald Balkissoon. (2023) Real-World Study of Single-Inhaler Triple Therapy with Fluticasone Furoate/Umeclidinium/Vilanterol on Asthma Control in the US. Journal of Asthma and Allergy 16, pages 1309-1322.
Read now
Read now
Mohamed Hamouda, Mohamed Farghaly & Sara Al Dallal. (2023) Budget Impact Analysis of Single-Inhaler Fluticasone Furoate/Umeclidinium/Vilanterol in Patients with Asthma in the Dubai Academic Healthcare Corporation. ClinicoEconomics and Outcomes Research 15, pages 549-558.
Read now
Read now
Soichiro Hozawa, Hiroyuki Ohbayashi, Michiko Tsuchiya, Yu Hara, Laurie A Lee, Takashi Nakayama, Jun Tamaoki, Andrew Fowler & Takanobu Nishi. (2021) Safety of Once-Daily Single-Inhaler Triple Therapy with Fluticasone Furoate/Umeclidinium/Vilanterol in Japanese Patients with Asthma: A Long-Term (52-Week) Phase III Open-Label Study. Journal of Asthma and Allergy 14, pages 809-819.
Read now
Read now
Carlyne M Averell, David Hinds, Jolyon Fairburn-Beech, Benjamin Wu & Robson Lima. (2021) Characteristics of Treated Asthmatics Experiencing Exacerbations in a US Database: A Retrospective Cohort Study. Journal of Asthma and Allergy 14, pages 755-771.
Read now
Read now
Yoichi Nakamura, Soichiro Hozawa, Hironori Sagara, Hiroyuki Ohbayashi, Laurie A. Lee, Jodie Crawford, Jun Tamaoki, Takanobu Nishi & Andrew Fowler. (2021) Efficacy and safety of once-daily, single-inhaler fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol in Japanese patients with inadequately controlled asthma: the CAPTAIN study. Current Medical Research and Opinion 37:9, pages 1657-1665.
Read now
Read now
Christina Joanne Pearce & Louise Fleming. (2018) Adherence to medication in children and adolescents with asthma: methods for monitoring and intervention. Expert Review of Clinical Immunology 14:12, pages 1055-1063.
Read now
Read now
Articles from other publishers (20)
Melissa H. Roberts, Mei Sheng Duh, Kieran J. Rothnie, Shiyuan Zhang, Alexandrosz Czira, David Slade, Wendy Y. Cheng, Philippe Thompson-Leduc, Alexandra Greatsinger, Adina Zhang & Douglas Mapel. (2024) Development and validation of a claims-based algorithm to identify moderate exacerbations in patients with asthma treated in the US. Respiratory Medicine 226, pages 107630.
Crossref
Crossref
Mei Sheng Duh, Melissa H. Roberts, Kieran J. Rothnie, Wendy Y. Cheng, Philippe Thompson-Leduc, Shiyuan Zhang, Alexandrosz Czira, David Slade, Alexandra Greatsinger, Adina Zhang & Douglas Mapel. (2024) Frequency and economic burden of exacerbations in inhaled corticosteroid/long-acting beta-agonist-treated patients with asthma: A retrospective US claims study. Respiratory Medicine 226, pages 107629.
Crossref
Crossref
Haihua Guo, Meng Li, Yue Lin, Zizhao Zhai, Guanlin Wang & Suqing Zhao. (2024) The Prophylactic Effects of Isosteviol Aerosol Inhalation on Bronchial Asthma in Mice. Pharmaceutical Chemistry Journal 57:12, pages 1872-1882.
Crossref
Crossref
Hiroyuki Nagase, Risako Ito, Moe Ishii, Hideki Shibata, Shintaro Suo, Isao Mukai, Shiyuan Zhang, Kieran J. Rothnie, Claire Trennery, Liza Yuanita & Takeo Ishii. (2023) Relationship Between Asthma Control Status and Health-Related Quality of Life in Japan: A Cross-Sectional Mixed-Methods Study. Advances in Therapy 40:11, pages 4857-4876.
Crossref
Crossref
Shiyuan Zhang, John White, Alyssa Goolsby Hunter, David Hinds, Andrew Fowler, Frances Gardiner, David Slade, Sharanya Murali & Wilhelmine Meeraus. (2023) Suboptimally controlled asthma in patients treated with inhaled ICS/LABA: prevalence, risk factors, and outcomes. npj Primary Care Respiratory Medicine 33:1.
Crossref
Crossref
Sharon M. Rymut, Lindsay M. Henderson, Victor Poon, Tracy L. Staton, Fang Cai, Siddharth Sukumaran, Horace Rhee, Ryan Owen, Saroja Ramanujan & Kenta Yoshida. (2023)
A mechanistic
PK
/
PD
model to enable dose selection of the potent anti‐tryptase antibody (
MTPS9579A
) in patients with moderate‐to‐severe asthma
. Clinical and Translational Science 16:4, pages 694-703.
Crossref
Crossref
Laura Hesse, J.N.G. Oude Elberink, Antoon J.M. van Oosterhout & Martijn C. Nawijn. (2022) Allergen immunotherapy for allergic airway diseases: Use lessons from the past to design a brighter future. Pharmacology & Therapeutics 237, pages 108115.
Crossref
Crossref
Thomas B. Casale, Michael B. Foggs & Ronald C. Balkissoon. (2022) Optimizing asthma management: Role of long-acting muscarinic antagonists. Journal of Allergy and Clinical Immunology 150:3, pages 557-568.
Crossref
Crossref
Mastiyage R Goonathilake, Sara Waqar, Sheeba George, Wilford Jean-Baptiste, Amina Yusuf Ali, Bithaiah Inyang, Feeba Sam Koshy, Kitty George, Prakar Poudel, Roopa Chalasani & Lubna Mohammed. (2022) Can Phosphodiesterase 4 Inhibitor Therapy Be Used in Respiratory Diseases Other Than Chronic Obstructive Pulmonary Disease?. Cureus.
Crossref
Crossref
V. V. Naumova, E. K. Beltyukov, V. Ch. Abdullaev & E. V. Shevtseva. (2022) The effectiveness of single inhaler triple therapy in patients with bronchial asthma in real clinical practice. Meditsinskiy sovet = Medical Council:4, pages 8-14.
Crossref
Crossref
Miriam Barrecheguren, Monica Monteagudo, Marc Miravitlles, Xavier Flor, Alexa Núñez, Jeisson Osorio, Xavier Muñoz & Iñigo Ojanguren. (2022) Characteristics and treatment patterns of patients with asthma on multiple-inhaler triple therapy in Spain. npj Primary Care Respiratory Medicine 32:1.
Crossref
Crossref
John Oppenheimer, Michael Bogart, Lindsay G.S. Bengtson, John White, Kevin Sundquist, Robson Lima & Carlyne Averell. (2022) Treatment Patterns and Disease Burden Associated with Multiple-Inhaler Triple-Therapy Use in Asthma. The Journal of Allergy and Clinical Immunology: In Practice 10:2, pages 485-494.e5.
Crossref
Crossref
Laura Hesse, J.N.G. Oude Elberink, Antoon J.M. van Oosterhout & Martijn C. Nawijn. (2022) Inmunoterapia con alérgenos para enfermedades alérgicas de las vías respiratorias: Aprovechar las lecciones del pasado para diseñar un futuro mejor. Kompass Neumología 4:2, pages 58-80.
Crossref
Crossref
Alexandrosz Czira, Monica Turner, Amber Martin, David Hinds, Helen Birch, Frances Gardiner & Shiyuan Zhang. (2022) A systematic literature review of burden of illness in adults with uncontrolled moderate/severe asthma. Respiratory Medicine 191, pages 106670.
Crossref
Crossref
Yasuhiro Gon, Naho Ohyanagi & Akihiro Kobayashi. (2021) The association between control level and self-reported treatment adherence across different treatment types in Japanese asthma patients. Respiratory Investigation 59:4, pages 454-463.
Crossref
Crossref
Shuying Yang, Laurie A. Lee, Neal Sule, Andrew Fowler & Guy Peachey. (2021) Population Pharmacokinetic Modeling of Fluticasone Furoate, Umeclidinium Bromide, and Vilanterol in Patients with Asthma, Using Data from a Phase IIIA Study (CAPTAIN). Clinical Pharmacokinetics 60:7, pages 887-896.
Crossref
Crossref
John Oppenheimer, David J. Slade, Beth A. Hahn, Laurie Zografos, Alicia Gilsenan, David Richardson, David McSorley, Robson Lima, Nestor A. Molfino & Carlyne M. Averell. (2021) Real-world evidence. Annals of Allergy, Asthma & Immunology 126:4, pages 385-393.e2.
Crossref
Crossref
Laurie A Lee, Zelie Bailes, Neil Barnes, Louis-Philippe Boulet, Dawn Edwards, Andrew Fowler, Nicola A Hanania, Huib A M Kerstjens, Edward Kerwin, Robert Nathan, John Oppenheimer, Alberto Papi, Steven Pascoe, Guy Brusselle, Guy Peachey, Neal Sule, Maggie Tabberer & Ian D Pavord. (2021) Efficacy and safety of once-daily single-inhaler triple therapy (FF/UMEC/VI) versus FF/VI in patients with inadequately controlled asthma (CAPTAIN): a double-blind, randomised, phase 3A trial. The Lancet Respiratory Medicine 9:1, pages 69-84.
Crossref
Crossref
Mohmmed Algamdi, Mohsen Sadatsafavi, Jolene H. Fisher, Julie Morisset, Kerri A. Johannson, Charlene D. Fell, Martin Kolb, Hélène Manganas, Gerard Cox, Andrea S. Gershon, Andrew J. Halayko, Nathan Hambly, Nasreen Khalil, Shane Shapera, Teresa To, Pearce G. Wilcox, Sabina Guler & Christopher J. Ryerson. (2019) Costs of Workplace Productivity Loss in Patients With Fibrotic Interstitial Lung Disease. Chest 156:5, pages 887-895.
Crossref
Crossref
Leif Bjermer, Katharine Abbott-Banner & Kenneth Newman. (2019) Efficacy and safety of a first-in-class inhaled PDE3/4 inhibitor (ensifentrine) vs salbutamol in asthma. Pulmonary Pharmacology & Therapeutics 58, pages 101814.
Crossref
Crossref